论文部分内容阅读
目的研究不同剂量降纤酶治疗急性脑梗死临床疗效和防止复发的作用。方法将符合入选标准病例 172例 ,随机分成A组 (全程总量 4 0U)和B组 (全程总量 2 0U) ,均分 4次稀释静脉给药。对比观察治疗前后临床神经功能缺损评分 (NDF) ,日常生活能力 (Barthel指数 )评估 ,纤维蛋白原 (FIB)含量。并随访 1年脑梗死复发率。结果A组治疗后NDF评分显著下降、Barthel指数明显提高 ,与治疗前比较有明显差异 (P <0 .0 5 ) ;血浆FIB含量显著下降 ,与治疗前比较有显著差异 (P <0 .0 1)。而B组治疗后 ,NDF评分、FIB含量有所下降 ,Barthel指数也有提高 ,但与治疗前比较无明显差异 (P >0 .0 5 )。而皮下出血、牙龈出血、应激性胃溃疡出血等副作用 ,两组比较 ,无统计学意义。结论国产降纤酶(沈阳光大制药厂 )A组全程总量为 4 0U ,治疗急性脑梗死疗效显著、防止近期复发明显优于全程总量为 2 0U的B组。
Objective To study the clinical effects of different doses of defibrase in the treatment of acute cerebral infarction and to prevent recurrence. Methods A total of 172 eligible patients were randomly divided into group A (total 4 0U) and group B (total 20 U). The changes of clinical neurological deficit score (NDF), daily living ability (Barthel index) and fibrinogen (FIB) content were compared before and after treatment. Follow-up 1-year recurrence rate of cerebral infarction. Results After treatment, the NDF score decreased significantly in group A, the Barthel index increased significantly compared with that before treatment (P <0.05); the content of FIB in plasma decreased significantly compared with that before treatment (P <0. 0 1). However, after treatment, the NDF score, FIB content decreased and Barthel index increased. However, there was no significant difference between the two groups (P> 0.05). The subcutaneous bleeding, bleeding gums, gastric ulcer and other side effects of stress, two groups, no statistical significance. Conclusion The total amount of domestic defibrase (Shenyang Guangda Pharmaceutical Factory) group A is 40U, the curative effect of treating acute cerebral infarction is significant, prevent the recent recurrence obviously better than the group B with the total amount of 20U.